|
Aug 8
|
Analysts Have Made A Financial Statement On Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Second-Quarter Report
|
|
Aug 5
|
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 5
|
Ocular Therapeutix: Q2 Earnings Snapshot
|
|
Aug 5
|
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights
|
|
Jul 29
|
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
|
|
Jul 22
|
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences
|
|
Jun 26
|
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
|
|
Jun 25
|
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
|
|
Jun 17
|
Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years
|
|
Jun 16
|
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
|
|
Apr 29
|
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
|
|
Apr 29
|
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences
|
|
Apr 28
|
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
|
|
Mar 14
|
Why Ocular Therapeutix Was Bumping Higher This Week
|
|
Mar 11
|
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
|